



New Federal Awards

Renata Pereira Alambert, PhD • *The role of the integrated stress response in brown adipose tissue-mediated metabolic adaptations—NIH R01*

Ryan Boudreau, PhD • *The physiologic and genomic relevance of mitoregulin in ischemic heart failure—NIH R01*

Joselyn Cho, MD • *Regulation of the host immune response to influenza by the checkpoint receptor Tim3—NIH R01*

Ayotunde Dokun, MD, PhD • *Modulation of miR29a and ADAM12 to improve peripheral arterial disease—NIH R01*

Isabella Grumbach, MD, PhD • *Laser speckle flowgraphy as early indicator of microvasculopathy in radiation-induced vision loss—NIH R01*

Kaiko Irani, MD, and Modar Kassan, PhD • *Harnessing a host microRNA that reshapes the microbiome to protect against hypothermia—DOD Navy*

Santosh Kumar, MD, PhD • *SUMO2-p66Shc axis in vascular endothelial dysfunction and atherosclerosis—NIH R01*

Barry London, MD, PhD • *Mechanisms of arrhythmias following cardiac irradiation—NIH R01*

Rasna Sabharwal, MS, PhD • *Stress-induced cardiovascular dysfunction in dilated cardiomyopathy—NIH R01*

Sam Stephens, PhD • *Exhausted protein sorting capacity impairs beta-cell function in Type 2 diabetes—DOD CDMRP*

Competitive Renewals

Dale Abel, MD, PhD • *OPA1: an estrogen-mediated modulator of platelet hyperactivation—NIH R33*

Barry London, MD, PhD, and Kaikobad Irani, MD • *Regulation of the cardiac sodium channel by sumoylation—NIH R01*



Other Awards

Linda Cadaret, MD • *Comparison of the efficacy and safety of macitentan and tadalafil monotherapies with the corresponding fix*—Janssen Research and Development, LLC

Linda Caderet, MD • *PB1046 Subcutaneous Injections in Pulmonary Arterial Hypertension Subjects Following Completion of Study*—PhaseBio Pharmaceuticals, Inc.

Alejandro Comellas, MD • *Canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia*

Muhammad Furqan, MD • *ALT-803 in combination with a PD-1 / PD-L1 checkpoint inhibitor in patients with disease progression following initial response to treatment with checkpoint inhibitor therapy*—Altor BioScience, LLC

Dilek Ince, MD • *Safety and Antiviral Activity of Remdesivir in Participants with Severe COVID-19*—Gilead Sciences, Inc.

Pashtoon Kasi, MD, MS • *Pemigatinib versus Gemcitabine plus Cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma*—Incyte Corporation

Varun Monga, MD • *Genetically engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ participants with NY-ESO-1 and/or LAGE-1a positive solid tumors*—PPD Investigator Services, LLC

Troy Rhodes, MD, PhD • *Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia*—Milestone Pharmaceuticals, Inc.

Antonio Jamie Sanchez, MD • *EDP-305 in subjects with proven non-alcoholic steatohepatitis*—ICON Clinical Research, LLC

Huy Tran, MD, PhD • *AK002 in adults/adolescents with active eosinophilic esophagitis*—Allakos, Inc.

Praveen Vikas, MBBS • *SAR439859 vs endocrine monotherapy as per physician's choice in premenopausal and postmenopausal patients with ER+, HER2-negative locally advanced or metastatic breast cancer with prior exposure to hormonal therapies*—Sanofi US Services Inc.

Pat Winokur, MD • *SARS-CoV-2 RNA vaccine candidates against COVID-19 in healthy adults*—Pfizer, Inc.